Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Novarad and PenRad Partner to Provide Further Diagnostic Tracking Functionality to Healthcare Providers

Healthcare IT company Novarad to offer PenRad’s PenLung automated tracking and reporting system for lung screening and lung cancer as part of its diagnostic suite

Novarad, a leading provider of medical software, announced that it has expanded its strategic partnership with mammography analytics company, PenRad, Inc. PenRad’s automated tracking and reporting system for lung screening, PenLung will integrate with Novarad’s NovaPACS with enterprise imaging.

The NovaPACS platform is focused on elevating patient health and efficiently managing workflows by providing a simple yet elegant solution to reading and reporting. The fully-integrated platform and its multiple components enable users to view many kinds of studies from a single workstation.

In addition to the products PenConnect and PenTrac, Novarad will be offering PenLung, a lung nodule tracking and reporting platform, as well as PenAlert. PenLung and PenAlert are automated solutions for reporting CT lung screening results for the nearly 50 separate abnormality profiles and 30 Lung-RADS combinations for audit and recall requirements. PenLung also facilitates upload to the National Lung CT Registry, which is a requirement for each lung cancer LDCT screening performed.

Recommended AI News: Ultraleap Raises £60 Million in Series D Fundraise to Be the Primary Interface for the Metaverse

“We are pleased to be able to add PenLung and PenAlert to the arsenal of products that arm radiologists with the tools to provide faster and more accurate diagnoses, which results in better patient care and reduced patient vulnerability,” said David Grandpre, Senior Director of Product at Novarad. “Recent changes in LDCT lung screening guidelines and an increase of 37% in payment for outpatient lung imaging will drive demand for more efficient workflow and analytics programs; NovaPACS with PenLung fits the bill.”

Related Posts
1 of 23,186

Recommended AI News: VeriSilicon Image Signal Processor IP Achieved ISO 26262 Automotive Functional Safety Certification

“PenLung Low Dose CT screening software provides radiology departments optimized workflow benefits and tracking efficiencies previously only required by women’s imaging programs” said Greg Gustafson, President and CEO of PenRad Technologies, Inc. Gustafson goes on to say, “the growth of PenLung is coincident with the expansion of LDCT lung screening programs across the U.S., and is being driven by the release of new LDCT screening guidelines.  This steady expansion gives us hope that early detection rates will rise in the coming years.”

PenRad and Novarad will be attending the 2021 Radiological Society of North America (RSNA) Annual Meeting, scheduled for Nov. 28 – Dec. 2, 2021 in Chicago, Illinois. Visit PenRad at booth #3117 and Novarad at booth #1729 to learn more about this new partnership and how it can help you meet both current and future healthcare demands.

Recommended AI News: Microsoft Loop Smooths Collaboration In The Hybrid Workplace

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.